We are live on ! Find out more
Candriam SCA

Candriam SCA Portfolio holdings

AUM $22.5B Turnover 10.3%
1-Year Est. Return 50.38%
 

Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.

This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+50.38%
3 Year Est. Return
+175.97%
5 Year Est. Return
+212.01%
10 Year Est. Return
+804.12%
AUM
$22.5B
AUM Growth
+$301M
Cap. Flow
-$416M
Cap. Flow %
-1.85%
Top 10 Hldgs %
34.05%
Holding
699
New
21
Increased
252
Reduced
270
Closed
51
Avg Time Held
6.2 years
Top 10 Avg Time Held
3.9 years
Top 20 Avg Time Held
3.4 years

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$98.2M
2
META icon
Meta Platforms (Facebook)
META
+$82.9M
3
NOW icon
ServiceNow
NOW
+$70.4M
4
INTC icon
Intel
INTC
+$58.4M
5
CRM icon
Salesforce
CRM
+$54.9M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$102M
2
PANW icon
Palo Alto Networks
PANW
+$102M
3
ABBV icon
AbbVie
ABBV
+$68.9M
4
AMZN icon
Amazon
AMZN
+$57M
5
NVDA icon
NVIDIA
NVDA
+$54.1M

Sector Composition

Rank Sector Weight
1 Technology 41.06%
2 Healthcare 24.01%
3 Financials 9.02%
4 Communication Services 7.08%
5 Consumer Discretionary 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MRVI icon
626
Maravai LifeSciences
MRVI
$1.07B
$138K ﹤0.01%
17,934
-5,661
-24% -$39.2K
2026 Q2
1 quarter
SBS icon
627
Sabesp
SBS
$16.2B
$136K ﹤0.01%
25,520
– –
2026 Q2
1 quarter
AMC icon
628
AMC Entertainment Holdings
AMC
$2.49B
$134K ﹤0.01%
+44,543
New +$111K
2026 Q3
0 quarters
CIG icon
629
CEMIG Preferred Shares
CIG
$5.15B
$101K ﹤0.01%
47,797
– –
2024 Q2
9 quarters
GRAB icon
630
Grab
GRAB
$11.8B
$31.3K ﹤0.01%
10,041
– –
2025 Q4
3 quarters
ACM icon
631
Aecom
ACM
$10.3B
– –
-40,592
Closed -$2.83M –
AGCO icon
632
AGCO
AGCO
$7.1B
– –
-2,213
Closed -$265K –
ALGN icon
633
Align Technology
ALGN
$11.3B
– –
-31,271
Closed -$5.27M –
ALV icon
634
Autoliv
ALV
$8.51B
– –
-33,176
Closed -$3.85M –
APGE icon
635
DELISTED
Apogee Therapeutics
APGE
– –
-79,684
Closed -$10.6M –
ARE icon
636
Alexandria Real Estate Equities
ARE
$7.27B
– –
-7,700
Closed -$407K –
ATAI icon
637
DELISTED
AtaiBeckley Inc
ATAI
– –
-3,039,399
Closed -$16M –
AVB icon
638
DELISTED
AvalonBay Communities
AVB
– –
-20,643
Closed -$3.89M –
BMA icon
639
Banco Macro
BMA
$3.29B
– –
-29,700
Closed -$2.75M –
BPOP icon
640
Popular Inc
BPOP
$9.28B
– –
-15,862
Closed -$2.6M –
BWA icon
641
BorgWarner
BWA
$10B
– –
-22,037
Closed -$1.46M –
CELC icon
642
Celcuity
CELC
$2.76B
– –
-72,588
Closed -$7.59M –
CF icon
643
CF Industries
CF
$16.9B
– –
-8,875
Closed -$960K –
CHE icon
644
Chemed
CHE
$7.15B
– –
-41,398
Closed -$19.3M –
CLX icon
645
Clorox
CLX
$12.7B
– –
-14,949
Closed -$1.43M –
CNP icon
646
CenterPoint Energy
CNP
$25.9B
– –
-100,151
Closed -$4.41M –
CPRX icon
647
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-55,795
Closed -$1.75M –
CRL icon
648
Charles River Laboratories
CRL
$16B
– –
-105,152
Closed -$23.8M –
CRNX icon
649
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-819,032
Closed -$30.6M –
CSGP icon
650
CoStar Group
CSGP
$11.5B
– –
-21,565
Closed -$610K –

Similar funds

Candriam SCA's Q3 2026 Portfolio in Review

As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
  • Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
  • Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
  • Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
  • Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
  • Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
  • Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.